Glibenclamide, a new sulphonylurea: whither oral hypoglycaemic agents?
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002241:Carbohydrates / Q000009:adverse effects; D002648:Child; D003327:Coronary Disease / Q000150:complications / Q000209:etiology; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy; D003927:Diet, Diabetic; D005227:Fatty Acids / Q000097:blood; D005905:Glyburide / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000097:blood / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000378:metabolism; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D014044:Tolbutamide / Q000009:adverse effects / Q000494:pharmacology / Q000633:toxicity
D001786:Blood Glucose; D002241:Carbohydrates; D005227:Fatty Acids; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D014044:Tolbutamide; D005905:Glyburide